Lentinan

Lentinan
(IUPAC) ime
	β-D-glukopiranozil-(1→6)-[β-D-glukopiranozil-(1→3)-[β-D-glukopiranozil-(1→6)]-β-D-glukopiranozil-(1→3)-β-D-glukopiranozil-(1→3)β-D-glukopiranozil-(1→3)]-β-D-glukopiranoza
Klinički podaci
AHFS/Drugs.com	Internacionalno ime leka
Identifikatori
CAS broj	37339-90-5
ATC kod	L03AX01
PubChem	37723
KEGG	D01695
Hemijski podaci
Formula	C42H72O36
Mol. masa	1152.99948 g/mol
SMILES	eMolekuli & PubHem
InChI
	InChI=InChI=1S/C42H72O36/c43-1-8-15(48)22(55)25(58)37(69-8)66-6-13-20(53)32(28(61)36(65)68-13)75-40-29(62)33(18(51)11(4-46)72-40)77-41-30(63)34(19(52)12(5-47)73-41)78-42-31(64)35(76-39-27(60)24(57)17(50)10(3-45)71-39)21(54)14(74-42)7-67-38-26(59)23(56)16(49)9(2-44)70-38/h8-65H,1-7H2/t8-,9-,10-,11-,12-,13-,14-,15-,16-,17-,18-,19-,20-,21-,22+,23+,24+,25-,26-,27-,28-,29-,30-,31-,32+,33+,34+,35+,36-,37-,38-,39+,40+,41+,42+/m1/s1; Key: MAXBMUKIXLNXGX-DMWITZOWSA-N
Sinonimi	(2S,3R,4S,5S,6R)-2-[(2S,3R,4S,5R,6R)-2-[(2S,3R,4S,5R,6R)-2-[(2R,3R,4S,5R,6S)-3,5-dihidroksi-2-(hidroksimetil)-6-[(2R,3R,4S,5R,6R)-2,3,5-trihidroksi-6-[[(2R,3R,4S,5S,6R)-3,4,5-trihidroksi-6-(hidroksimetil)oksan-2-il]oksimetil]oksan-4-il]oksioksan-4-il]oksi-3,5-dihidroksi-6-(hidroksimetil)oksan-4-il]oksi-3,5-dihidroksi-6-[[(2R,3R,4S,5S,6R)-3,4,5-trihidroksi-6-(hidroksimetil)oksan-2-il]oksimetil]oksan-4-il]oksi-6-(hidroksimetil)oksan-3,4,5-triol
Farmakoinformacioni podaci
Trudnoća	?
Pravni status

Lentinan je beta-glukan sa glikozidnim β-1,3:β-1,6 vezama.^[4] On je antitumorni polisaharid iz šitake (Lentinula edodes) pečurke.^[4] Lentinan je polisaharid sa molekulskom težinom od oko 500.000 Da. Japanska farmaceutska kompanija Ajinomoto je razvila lek Lentinan, koji se intravenozno dozira kao agens protiv kancera.^[5]

Lentinan je jedan od lekova protiv kancera^[6] za koji je pokazano da utiče na odbrambeni imunski sistem domaćina.^[7]

Klinička israživanja na obolelima od raka su ukazala na vezu između lentinana i povišenog stepena perživljavanja, poboljšanog kvaliteta života, i umanjene ponovne pojave kancera.^[8]^[9]^[10]^[11]^[12]^[13]^[14]^[15]

Reference

↑ Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519. edit
↑ Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.
↑ Joanne Wixon, Douglas Kell (2000). „Website Review: The Kyoto Encyclopedia of Genes and Genomes — KEGG”. Yeast 17 (1): 48–55. DOI:10.1002/(SICI)1097-0061(200004)17:1<48::AID-YEA2>3.0.CO;2-H.
↑ ^4,0 ^4,1 Cancer Guide Arhivirano 2012-12-31 na Wayback Machine-u Includes many abstracts
↑ „Medicinal Mushrooms:Their therapeutic properties and current medicalusage with special emphasis on cancer treatments”.
↑ Nakano H, Namatame K, Nemoto H, Motohashi H, Nishiyama K, Kumada K (1999). „A multi-institutional prospective study of lentinan in advanced gastric cancer patients with unresectable and recurrent diseases: effect on prolongation of survival and improvement of quality of life. Kanagawa Lentinan Research Group.”. Hepatogastroenterology 46 (28): 2662–8. PMID 10522061.
↑ Nakano H, Namatame K, Nemoto H, Motohashi H, Nishiyama K, Kumada K (1999). „A multi-institutional prospective study of lentinan in advanced gastric cancer patients with unresectable and recurrent diseases: effect on prolongation of survival and improvement of quality of life. Kanagawa Lentinan Research Group”. Hepatogastroenterology 46 (28): 2662–8. PMID 10522061.
↑ Yang P, Liang M, Zhang Y, Shen B. (Aug 2008). „Clinical application of a combination therapy of lentinan, multi-electrode RFA and TACE in HCC.”. Adv Ther. 25 (8): 787–94. DOI:10.1007/s12325-008-0079-x. PMID 18670743
↑ Nimura H, Mitsumori N, Takahashi N, (Jun 2006). „[S-1 combined with lentinan in patients with unresectable or recurrent gastric cancer]”. Gan to Kagaku Ryoho. 33 (1): 106–9. PMID 16897983
↑ Nakano H, Namatame K, Nemoto H, Motohashi H, Nishiyama K, Kumada K. (1999). „A multi-institutional prospective study of lentinan in advanced gastric cancer patients with unresectable and recurrent diseases: effect on prolongation of survival and improvement of quality of life. Kanagawa Lentinan Research Group.”. Hepatogastroenterology. 46 (28): 2662–8. PMID 10522061
↑ Oba K, Kobayashi M, Matsui T, Kodera Y, Sakamoto J (July 2009). „Individual Patient Based Meta-analysis of Lentinan for Unresectable/Recurrent Gastric Cancer”. Anticancer Res. 29 (7): 2739–45. PMID 19596954.
↑ Hazama S, Watanabe S, Ohashi M, et al. (July 2009). „Efficacy of Orally Administered Superfine Dispersed Lentinan ({beta1,3-Glucan) for the Treatment of Advanced Colorectal Cancer”. Anticancer Res. 29 (7): 2611–7. PMID 19596936.
↑ Kataoka H, Shimura T, Mizoshita T, et al. (2009). „Lentinan with S-1 and paclitaxel for gastric cancer chemotherapy improve patient quality of life”. Hepatogastroenterology 56 (90): 547–50. PMID 19579640.
↑ Isoda N, Eguchi Y, Nukaya H, et al. (2009). „Clinical efficacy of superfine dispersed lentinan (beta-1,3-glucan) in patients with hepatocellular carcinoma”. Hepatogastroenterology 56 (90): 437–41. PMID 19579616.
↑ Shimizu K, Watanabe S, Watanabe S, et al. (2009). „Efficacy of oral administered superfine dispersed lentinan for advanced pancreatic cancer”. Hepatogastroenterology 56 (89): 240–4. PMID 19453066.

Literatura

Chihara, G. et al. ”Fractionation and purification of the polysaccharides with marked antitumor activity, especially lentinan, from Lentinus edodes (Berk.) Sing. (an edible mushroom)”, Cancer Research (1970),30(11):2776-2781.
Ina, K. et al. “Lentinan prolonged survival in patients with gastric cancer receiving S-1-based chemotherapy”, World Journal of Clinical Oncology (2011),2(10):339-343.

Povezano

Medicinske pečurke

Spoljašnje veze

Lentinan effects (antitumor and others)

[1] Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519. edit

[2] Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.

[3] Joanne Wixon, Douglas Kell (2000). „Website Review: The Kyoto Encyclopedia of Genes and Genomes — KEGG”. Yeast 17 (1): 48–55. DOI:10.1002/(SICI)1097-0061(200004)17:1<48::AID-YEA2>3.0.CO;2-H.

[CancerGuide-4] 4,0 ^4,1 Cancer Guide Arhivirano 2012-12-31 na Wayback Machine-u Includes many abstracts

[5] „Medicinal Mushrooms:Their therapeutic properties and current medicalusage with special emphasis on cancer treatments”.

[pmid10522061-6] Nakano H, Namatame K, Nemoto H, Motohashi H, Nishiyama K, Kumada K (1999). „A multi-institutional prospective study of lentinan in advanced gastric cancer patients with unresectable and recurrent diseases: effect on prolongation of survival and improvement of quality of life. Kanagawa Lentinan Research Group.”. Hepatogastroenterology 46 (28): 2662–8. PMID 10522061.

[7] Nakano H, Namatame K, Nemoto H, Motohashi H, Nishiyama K, Kumada K (1999). „A multi-institutional prospective study of lentinan in advanced gastric cancer patients with unresectable and recurrent diseases: effect on prolongation of survival and improvement of quality of life. Kanagawa Lentinan Research Group”. Hepatogastroenterology 46 (28): 2662–8. PMID 10522061.

[pmid_=_18670743-8] Yang P, Liang M, Zhang Y, Shen B. (Aug 2008). „Clinical application of a combination therapy of lentinan, multi-electrode RFA and TACE in HCC.”. Adv Ther. 25 (8): 787–94. DOI:10.1007/s12325-008-0079-x. PMID 18670743

[pmid_=_16897983-9] Nimura H, Mitsumori N, Takahashi N, (Jun 2006). „[S-1 combined with lentinan in patients with unresectable or recurrent gastric cancer]”. Gan to Kagaku Ryoho. 33 (1): 106–9. PMID 16897983

[pmid_=_10522061-10] Nakano H, Namatame K, Nemoto H, Motohashi H, Nishiyama K, Kumada K. (1999). „A multi-institutional prospective study of lentinan in advanced gastric cancer patients with unresectable and recurrent diseases: effect on prolongation of survival and improvement of quality of life. Kanagawa Lentinan Research Group.”. Hepatogastroenterology. 46 (28): 2662–8. PMID 10522061

[pmid19596954-11] Oba K, Kobayashi M, Matsui T, Kodera Y, Sakamoto J (July 2009). „Individual Patient Based Meta-analysis of Lentinan for Unresectable/Recurrent Gastric Cancer”. Anticancer Res. 29 (7): 2739–45. PMID 19596954.

[pmid19596936-12] Hazama S, Watanabe S, Ohashi M, et al. (July 2009). „Efficacy of Orally Administered Superfine Dispersed Lentinan ({beta1,3-Glucan) for the Treatment of Advanced Colorectal Cancer”. Anticancer Res. 29 (7): 2611–7. PMID 19596936.

[pmid19579640-13] Kataoka H, Shimura T, Mizoshita T, et al. (2009). „Lentinan with S-1 and paclitaxel for gastric cancer chemotherapy improve patient quality of life”. Hepatogastroenterology 56 (90): 547–50. PMID 19579640.

[pmid19579616-14] Isoda N, Eguchi Y, Nukaya H, et al. (2009). „Clinical efficacy of superfine dispersed lentinan (beta-1,3-glucan) in patients with hepatocellular carcinoma”. Hepatogastroenterology 56 (90): 437–41. PMID 19579616.

[pmid19453066-15] Shimizu K, Watanabe S, Watanabe S, et al. (2009). „Efficacy of oral administered superfine dispersed lentinan for advanced pancreatic cancer”. Hepatogastroenterology 56 (89): 240–4. PMID 19453066.

[1]